For NeurogesX, a small biopharma company based in San Mateo, CA, time does not stand still. Every day preceding November 16 brings its flagship drug, Qutenza, one step closer to approval. Until then, the company has turned its energies to finalizing its US commercialization strategy. (NeurogesX previously entered into a commercialization agreement with Astellas Pharma [...]
PharmExec Blog
Follow Us
RSS
Bookstore
A Lead Drug on the Way? All Eyes on FDA